September 2, 2016

Discovery of New Chemical Entities for Alzheimer's Disease Tauopathy

The project is supported by a Phase I SBIR grant award from the National Institute on Aging (1R43AG053137-01A1). Experimental work will be subcontracted to the laboratory of Dr. Kuret at Ohio State University.

Project Narrative:
Alzheimer’s disease is the most prevalent dementing illness of the elderly. It is defined in part by the appearance of cellular lesions composed of aggregates of the microtubule-associated protein tau. This project seeks to identify novel tau aggregation inhibitors as potentially disease modifying therapeutics for AD.

Link to NIH RePORT